MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2004.10.050

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2004

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Thomas Xavier, Boiron Jean-Michel, Huguet Françoise, Dombret Hervé, Bradstock Ken, Vey Norbert, Kovacsovics Tibor, Delannoy André, Fegueux Nathalie, Fenaux Pierre, Stamatoullas Aspasia, Vernant Jean-Paul, Tournilhac Olivier, Buzyn Agnès, Reman Oumedaly, Charrin Christiane, Boucheix Claude, Gabert Jean, Lhéritier Véronique, Fiere Denis

Клиническое исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: We analyzed the benefits of a risk-adapted postremission strategy in adult lymphoblastic leukemia (ALL), and re-evaluated stem-cell transplantation (SCT) for high-risk ALL.

PATIENTS AND

METHODS

A total of 922 adult patients entered onto the trial according to risk groups: standard-risk ALL (group 1), high-risk ALL (group 2), Philadelphia chromosome-positive ALL (group 3), and CNS-positive ALL (group 4). All received a standard four-drug/4-week induction course. Patients from group 1 who achieved a complete remission (CR) after one course of induction therapy were randomly assigned between intensive and less intensive postremission chemotherapy, whereas those who achieved CR after salvage therapy were then included in group 2. Patients in groups 2, 3, and 4 with an HLA-identical sibling were assigned to allogeneic SCT. In groups 3 and 4, autologous SCT was offered to all other patients, whereas in group 2 they were randomly assigned between chemotherapy and autologous SCT.

RESULTS

Overall, 771 patients achieved CR (84%). Median disease-free survival (DFS) was 17.5 months, with 3-year DFS at 37%. In group 1, the 3-year DFS rate was 41%, with no difference between arms of postremission randomization. In groups 2 and 4, the 3-year DFS rates were 38% and 44%, respectively. In group 2, autologous SCT and chemotherapy resulted in comparable median DFS. Patients with an HLA-matched sibling (groups 2 and 4) had improved DFS. Three-year DFS was 24% in group 3.

CONCLUSION

Allogeneic SCT improved DFS in high-risk ALL in the first CR. Autologous SCT did not confer a significant benefit over chemotherapy for high-risk ALL.

Для цитирования: Thomas Xavier, Boiron Jean-Michel, Huguet Françoise, Dombret Hervé, Bradstock Ken, Vey Norbert, Kovacsovics Tibor, Delannoy André, Fegueux Nathalie, Fenaux Pierre, Stamatoullas Aspasia, Vernant Jean-Paul, Tournilhac Olivier, Buzyn Agnès, Reman Oumedaly, Charrin Christiane, Boucheix Claude, Gabert Jean, Lhéritier Véronique, Fiere Denis. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. DOI: 10.1200/jco.2004.10.050.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.